Friday September 06, 2013

Dynamic sales growth: +34% (+35% at constant exchange rates) reflect successful integration into QIAGEN group

QIAGEN Marseille (Alternext - FR0010626028 - ALIPS), a subsidiary of the QIAGEN Group (previously IPSOGEN), a cancer profiling company that develops, manufactures and markets molecular diagnostic tests for leukemia and cancer, today announced revenues for the first half year 2013.

Total revenue reached 7.6 M€ compared with 5.7 M€ in the first six months of 2012, an increase of +34% over the same period in 2012 (+35% at constant foreign exchange rate).

See press release

distributed by